Is Rallybio Corp (RLYB) Halal?

NASDAQ Healthcare United States $43M
✗ NOT HALAL
Confidence: 83/100
Rallybio Corp (RLYB) is Not Halal under AAOIFI Standard 21. While the debt ratio of 0.3% is acceptable, the cash and interest-bearing securities ratio of 113.7% exceeds the 30% threshold. Rallybio Corp operates in the Healthcare sector.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI 0.3%
/ 30%
113.7%
/ 30%
0.0%
/ 30%
662.89%
/ 5%
✗ NOT HALAL
DJIM 0.3%
/ 33%
113.7%
/ 33%
0.0%
/ 33%
662.89%
/ 5%
✗ NOT HALAL
MSCI 0.2%
/ 33%
96.2%
/ 33%
0.0%
/ 33%
662.89%
/ 5%
✗ NOT HALAL
S&P 0.3%
/ 33%
113.7%
/ 33%
0.0%
/ 33%
662.89%
/ 5%
✗ NOT HALAL
FTSE 0.2%
/ 33%
96.2%
/ 33%
0.0%
/ 50%
662.89%
/ 5%
✗ NOT HALAL

Financial Highlights

EPS
$-1.59
P/B Ratio
0.7
EV/EBITDA
0.4
EV: -$11M
Revenue
$858,000
Growth: 484.2%
Beta
-1.1
Low volatility
Current Ratio
14.5

Profitability

Gross Margin 0.0%
Operating Margin -2888.3%
Net Margin 0.0%
Return on Equity (ROE) -15.0%
Return on Assets (ROA) -30.1%

Cash Flow & Balance Sheet

Operating Cash Flow-$30M
Free Cash Flow-$30M
Total Debt$176,000
Debt-to-Equity0.3
Current Ratio14.5
Total Assets$62M

Price & Trading

Last Close$8.44
50-Day MA$6.98
200-Day MA$5.17
Avg Volume132K
Beta-1.1
52-Week Range
$1.76
$11.49

About Rallybio Corp (RLYB)

CEO
Dr. Stephen Uden M.D., MBBS
Employees
14
Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
NASDAQ
Market Cap
$43M
Currency
USD

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is Rallybio Corp (RLYB) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), Rallybio Corp is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is Rallybio Corp's debt ratio?

Rallybio Corp's debt ratio is 0.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.2%.

What are Rallybio Corp's key financial metrics?

Rallybio Corp has a market capitalization of $43M, and revenue of $858,000. Return on equity stands at -15.0%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.